Dabigatran Etexilate Synthesis via Phase Transfer Catalysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing synthesis process for dabigatran etexilate and analogous compounds is inefficient and generates excessive acids, requiring the development of a more selective and environmentally friendly method.
Innovation Solution
A new synthesis process using phase transfer catalysis and alternative starting materials, specifically reacting p-aminobenzamidine with haloacetic acid anhydrides or ortho-haloacetates, eliminates the need for coupling reagents and reduces acid production, achieving high selectivity and efficiency in the formation of dabigatran etexilate.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of substance
If the existing synthesis process using substituted (4-benzimidazol-2-ylmethylamino)-benzonitriles with ammonia is used, then dabigatran etexilate can be produced, but the process is extremely onerous and generates a large quantity of acids that have to be disposed of
Solution Approach 1:
The patent changes the chemical parameters of the synthesis route by using alternative starting materials (4-aminobenzamidine and haloacetic acid derivatives) and different reaction conditions (phase transfer catalysis, microwave irradiation) to transform the reaction pathway, thereby reducing acid waste generation while simplifying the manufacturing process
Solution Approach 2:
The patent extracts and eliminates the problematic ammonia reaction step and coupling reagents from the synthesis pathway, replacing them with a more efficient direct substitution reaction that avoids generating large quantities of acidic waste products
2Productivity
If coupling reagents are used in the synthesis process, then the reaction can proceed, but the process becomes less efficient and more costly
Solution Approach 1:
The patent removes coupling reagents entirely from the synthesis pathway by using alternative starting materials that react directly without requiring additional coupling agents, thereby simplifying the process steps and improving synthesis efficiency
Solution Approach 2:
The patent introduces phase transfer catalysts as intermediaries to facilitate the reaction between 4-aminobenzamidine and haloacetic acid derivatives, enabling the reaction to proceed efficiently without requiring coupling reagents
3Ease of manufacture
If the existing synthesis route is used, then dabigatran etexilate can be manufactured, but operational costs are high due to acid disposal requirements
Solution Approach 1:
The patent converts the harmful acid waste problem into a benefit by selecting starting materials and reaction conditions that inherently produce minimal acidic byproducts, eliminating the need for costly acid disposal operations while maintaining effective dabigatran etexilate production
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new process significantly improves the synthesis efficiency and selectivity, reducing waste generation and operational costs, while maintaining high product purity and reaction speed.
Implementation Method 1
A new synthesis process using phase transfer catalysis and alternative starting materials, specifically reacting p-aminobenzamidine with haloacetic acid anhydrides or ortho-haloacetates
Data Source
AI summary
An improved process for preparing dabigatran etexilate, as well as analogous compounds of formula 7,is described.